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Abstract

Results

Conclusion

Endometriosis is a chronic gynecological condition that can cause
dysmenorrhea, pelvic pain, and dyspareunia. Standard treatments,
including both pharmacologic therapy and surgery, can often fail and
patients still feel endometriosis related pain. Newer pharmacologic
agents (elagolix) that affect the gonadotropin releasing hormone (GnRH)
receptors have been developed specifically to treat endometriosis
associated symptoms. The purpose of this paper was to compare the
efficacy of these new medications to the already established efficacy of
oral contraceptive pills and NSAIDs.

Of the five studies analyzed in this paper, only one study
directly compared the use of GnRH medications to oral
contraceptive pills. Two studies compared GnRH medications
to placebo, one compared oral contraceptive pills to NSAIDs,
and one looked at the long-term effects of GnRH
medications. While the focus of each article was different, all
evaluated at least one of the following outcomes:
improvement in dysmenorrhea, non-menstrual pelvic pain,
or dyspareunia. The results indicate that GnRH medications
do
improve
endometriosis
related
pain,
but
the
benefit
over
Table 1. Comparison of Study Design
OCPs was not statistically significant.

The studies looking at GnRH medications had positive results—all
indicated that they reduce endometriosis related pain. However, one
study does not show benefit of these medications over OCPs—it
indicated that both had comparable efficacy in treating endometriosis
related pain. Another study showed negative long-term health effects of
these medications.

Table 2. Summary of Results
Study

Introduction
Endometriosis is a gynecological condition that affects females of
reproductive age, and 50% of women with infertility. This condition is
characterized by growth of endometrial-like tissue outside of the uterus,
and can cause dysmenorrhea, pelvic pain, and dyspareunia. The standard
first line medications include oral contraceptive pills—which aim to
suppress ovulation and menses—used in combination with NSAIDs. If
pharmacological therapy fails and patients still experience pain, surgical
intervention is often necessary. However, many patients still experience
pain regardless of these therapies, so it is important to explore other
treatment options. Newer pharmacologic agents that affect the
gonadotropin releasing hormone (GnRH) receptors have been developed
specifically to treat endometriosis associated symptoms. Thus, this paper
poses the following question: in females with endometriosis [P], are
medications that affect GnRH receptors [I] more effective at treatment
of pain [O] than oral contraceptives or NSAIDs [C]?

Methods
A literature search was conducted through the Pennsylvania State
University Libraries and PubMed in November 2019. After this search five
articles were chosen based on their relevance to the PICO question, year
of publication, study design, and outcome measurements. The results of
these articles were then compared.

Improvement in
Dyspareunia
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Dysmenorrhea Non-Menstrual
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Key: S = statistically significant; NS = non-significant; NA = not applicable (the study
did not measure this value)

Discussion
Positive results were found for the intervention being looked
at in each article, however they showed no significant
difference between GnRH medications and OCPs. The
blinding, timeline, and follow up were found to be
“adequate” for the majority of the articles, while potential
biases were found to be “moderate” for the majority of the
articles. In order to better compare and evaluate these
medications, further research should focus on:

Future
Research

•Direct comparison of GnRH medications,
OCPs, and NSAIDS
•Longer study length
•Less potential for observer bias

The results from these studies as a whole do not seem to support the
use of GnRH medications over OCPs, and the risks do not seem to
outweigh the benefits.
There is not enough evidence to support the use of GnRH medications
over the traditional therapy of OCPs. For clinical practice this means that
OCPs may currently remain the best therapy for endometriosis. Despite
this, the evidence surrounding GnRH medications is promising, and more
research in this area could further reveal its efficacy and safety. If
clinicians should choose to prescribe these medications, they should
weigh the risks and benefits on a case by case basis, since different
patients can respond differently. Going forward, clinicians should try to
stay up to date on this ongoing body of research to remain
knowledgeable of the role of GnRH medications in the treatment of
endometriosis related pain.
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